pT1N1M0早期胃癌术后辅助治疗临床意义的探索
The Clinical Significance of Postoperative Adjuvant Therapy for pT1N1M0 Early Gastric Cancer
DOI: 10.12677/acm.2024.14112895, PDF,   
作者: 荆瑶瑶*, 赵佳宇：青岛大学医学部，山东 青岛；刘自民#：青岛大学附属医院消化肿瘤诊疗中心，山东 青岛
关键词: pT1N1M0；早期胃癌；预后；辅助化疗；辅助放疗；pT1N1M0； Early Gastric Cancer； Prognosis； Adjuvant Chemotherapy； Adjuvant Radiotherapy
摘要: 背景：pT1N1M0分期胃癌术后辅助治疗目前各大指南无统一共识。本研究的目的是确定辅助放化疗对pT1N1M0胃癌根治术后患者有无生存获益，分析影响pT1N1M0胃癌患者预后的危险因素。方法：从SEER数据库中选择2004年至2019年胃切除术后pT1N1M0 GC患者319例。采用Kaplan-Meier法和log-rank检验分析总生存率。采用Cox比例风险回归模型对影响pT1N1M0胃癌根治性切除患者预后的因素进行单变量和多变量分析。结果：生存分析显示术后辅助化疗(5年OS：52.4% vs. 75.8%，p < 0.001)和辅助放疗(5年OS: 59.9% vs. 71.9%，p = 0.001)可显著延长pT1N1M0胃癌患者的生存期。多因素Cox回归分析显示年龄(p = 0.001)，原发部位(p = 0.009)，检查淋巴结数量(ELNC) (p = 0.007)和辅助化疗(p = 0.006)是与OS相关的独立预后因素。这些变量符合Cox回归比例风险假设检验(p > 0.05)。结论：术后辅助化疗及辅助放疗能够改善pT1N1M0 GC患者OS，年龄、辅助化疗、肿瘤部位、ELNC是pT1N1M0胃癌预后的独立影响因素。
Abstract: Background: Currently, there is no consensus on postoperative adjuvant therapy for pT1N1M0 gastric cancer in major guidelines. The aim of this study is to determine the survival benefit of adjuvant chemoradiotherapy in patients with pT1N1M0 gastric cancer after radical gastrectomy, and to analyze the risk factors affecting the prognosis of patients with pT1N1M0 gastric cancer. Methods: A total of 319 patients with pT1N1M0 GC after gastrectomy from 2004 to 2019 were selected from the SEER database. Kaplan-Meier method and log-rank test were used to analyze the overall survival rate. Univariate and multivariate analyses of prognostic factors of patients with pT1N1M0 gastric cancer after radical resection were performed using Cox proportional hazards regression model. Results: Survival analysis showed that postoperative adjuvant chemotherapy (5-year OS: 52.4% vs. 75.8%, p < 0.001) and adjuvant radiotherapy (5-year OS: 59.9% vs. 71.9%, p = 0.001) could significantly prolong the survival of patients with pT1N1M0 gastric cancer. Multivariate Cox regression analysis showed that age (p = 0.001), primary site (p = 0.009), number of examined lymph node count (ELNC) (p = 0.007) and adjuvant chemotherapy (p = 0.006) were independent prognostic factors associated with OS. These variables were in accordance with the Cox regression proportional hazards hypothesis test (p > 0.05). Conclusions: Postoperative adjuvant chemotherapy and radiotherapy can improve the OS of patients with pT1N1M0 GC. Age, adjuvant chemotherapy, tumor location, and ELNC are independent prognostic factors for pT1N1M0 gastric cancer.
文章引用：荆瑶瑶, 赵佳宇, 刘自民. pT1N1M0早期胃癌术后辅助治疗临床意义的探索[J]. 临床医学进展, 2024, 14(11): 416-425. https://doi.org/10.12677/acm.2024.14112895

参考文献

[1] Washington, K. (2010) 7th Edition of the AJCC Cancer Staging Manual: Stomach. Annals of Surgical Oncology, 17, 3077-3079. [Google Scholar] [CrossRef] [PubMed]
[2] Japanese Gastric Cancer Association (2011) Japanese Classification of Gastric Carcinoma: 3rd English Edition. Gastric Cancer, 14, 101-112. [Google Scholar] [CrossRef] [PubMed]
[3] Kim, S.M., An, J.Y., Lee, J., Sohn, T.S. and Kim, S. (2018) Adjuvant Chemotherapy versus Chemoradiotherapy versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis. Annals of Surgical Oncology, 25, 1616-1624. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, X. and Sun, Y. (2022) Recurrence of Early Gastric Cancer: Risk Factors and Patterns. Chinese Journal of Practical Surgery, 42, 1104-1107.
[5] Wang, H., Zhou, Y., Niu, Z., et al. (2015) The Risk Factors Relating to Prognosis and Recurrence after Curative Surgery in 539 Early Gastric Cancer Patients. Chinese Journal of General Surgery, 30, 639-642.
[6] Michel, M., Stevens, L., Armstrong, G., et al. (2014) Recurrence Patterns and Prognosis after Gastrectomy for pT1 Gastric Adenocarcinoma (Early Gastric Cancer). British Journal of Surgery, 101, 39-40.
[7] Maehara, Y., Kakeji, Y., Oda, S., Baba, H. and Sugimachi, K. (2001) Tumor Growth Patterns and Biological Characteristics of Early Gastric Carcinoma. Oncology, 61, 102-112. [Google Scholar] [CrossRef] [PubMed]
[8] Japanese Gastric Cancer Association (2022) Japanese Gastric Cancer Treatment Guidelines 2021 (6th Edition). Gastric Cancer, 26, 1-25. [Google Scholar] [CrossRef] [PubMed]
[9] Wu, Q., Jiang, J., Li, Z., Ling, X., Qiao, Z. and Ma, Y. (2024) Long-Term Survival Outcomes of Endoscopic Therapy vs. Surgical Resection in Patients with Cardia Gastrointestinal Stromal Tumor. PLOS ONE, 19, e0306598. [Google Scholar] [CrossRef] [PubMed]
[10] Lai, J.F., Kim, S., Kim, K., Li, C., Oh, S.J., Hyung, W.J., et al. (2009) Prediction of Recurrence of Early Gastric Cancer after Curative Resection. Annals of Surgical Oncology, 16, 1896-1902. [Google Scholar] [CrossRef] [PubMed]
[11] Tanimura, S., Higashino, M., Fukunaga, Y., Takemura, M., Tanaka, Y., Fujiwara, Y., et al. (2008) Laparoscopic Gastrectomy for Gastric Cancer: Experience with More than 600 Cases. Surgical Endoscopy, 22, 1161-1164. [Google Scholar] [CrossRef] [PubMed]
[12] Yuasa, N. and Nimura, Y. (2004) Survival after Surgical Treatment of Early Gastric Cancer, Surgical Techniques, and Long-Term Survival. Langenbeck’s Archives of Surgery, 390, 286-293. [Google Scholar] [CrossRef] [PubMed]
[13] Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., et al. (2011) Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy with S-1 versus Surgery Alone in Stage II or III Gastric Cancer. Journal of Clinical Oncology, 29, 4387-4393. [Google Scholar] [CrossRef] [PubMed]
[14] Noh, S.H., Park, S.R., Yang, H., Chung, H.C., Chung, I., Kim, S., et al. (2014) Adjuvant Capecitabine plus Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): 5-Year Follow-Up of an Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 15, 1389-1396. [Google Scholar] [CrossRef] [PubMed]
[15] Yoshida, K., Kodera, Y., Kochi, M., Ichikawa, W., Kakeji, Y., Sano, T., et al. (2019) Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients with Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. Journal of Clinical Oncology, 37, 1296-1304. [Google Scholar] [CrossRef] [PubMed]
[16] Park, S.H., Lim, D.H., Sohn, T.S., Lee, J., Zang, D.Y., Kim, S.T., et al. (2021) A Randomized Phase III Trial Comparing Adjuvant Single-Agent S1, S-1 with Oxaliplatin, and Postoperative Chemoradiation with S-1 and Oxaliplatin in Patients with Node-Positive Gastric Cancer after D2 Resection: The ARTIST 2 Trial. Annals of Oncology, 32, 368-374. [Google Scholar] [CrossRef] [PubMed]
[17] Smalley, S.R., Benedetti, J.K., Haller, D.G., Hundahl, S.A., Estes, N.C., Ajani, J.A., et al. (2012) Updated Analysis of Swog-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy versus Observation after Curative Gastric Cancer Resection. Journal of Clinical Oncology, 30, 2327-2333. [Google Scholar] [CrossRef] [PubMed]
[18] Hester, C.A., Augustine, M.M., Mansour, J.C., Polanco, P.M., Yopp, A.C., Zeh, H.J., et al. (2018) Adjuvant Therapy Is Associated with Improved Survival in Pt1n1 Gastric Cancer in a Heterogeneous Western Patient Population. Annals of Surgical Oncology, 26, 167-176. [Google Scholar] [CrossRef] [PubMed]
[19] Pan, S., Yin, S., Zhu, Z., Liu, F. and Xu, H. (2021) Decision-making of Adjuvant Therapy in pT1N1M0 Gastric Cancer: Should Radiotherapy Be Added to Chemotherapy? A Propensity Score-Matched Analysis. Journal of Cancer, 12, 1179-1189. [Google Scholar] [CrossRef] [PubMed]
[20] Mei, Y., Feng, T., Yan, M., Zhu, Z. and Zhu, Z. (2021) Is Adjuvant Chemotherapy Necessary for Early Gastric Cancer? Cancer Biology & Medicine, 19, 518-532. [Google Scholar] [CrossRef] [PubMed]
[21] Chen, Q., Xiao, H., Zhang, L., You, J., Jin, Z. and Zhang, B. (2022) Association between Adjuvant Chemotherapy and Survival in Stage I Gastric Cancer Patients after Curative Resection. Gastroenterology Report, 11, goad070. [Google Scholar] [CrossRef] [PubMed]
[22] Russo, A.E. and Strong, V.E. (2019) Gastric Cancer Etiology and Management in Asia and the West. Annual Review of Medicine, 70, 353-367. [Google Scholar] [CrossRef] [PubMed]
[23] Lee, I., Kang, H.J., Park, Y., Ryu, M., Yook, J., Kang, Y., et al. (2018) Prognostic Impact of Extranodal Extension in Stage 1B Gastric Carcinomas. Surgical Oncology, 27, 299-305. [Google Scholar] [CrossRef] [PubMed]
[24] Osumi, H., Yoshio, T., Chin, K., Ogura, M., Kumekawa, Y., Suenaga, M., et al. (2015) Chemotherapy Is Effective for Stage I Gastric Cancer in Patients with Synchronous Esophageal Cancer. Gastric Cancer, 19, 625-630. [Google Scholar] [CrossRef] [PubMed]
[25] Gao, X., Li, G., Deng, J., Zhao, L., Han, W., Zhang, N., et al. (2024) Association of Survival with Adjuvant Chemotherapy in Patients with Stage IB Gastric Cancer: A Multicentre, Observational, Cohort Study. The Lancet Regional Health—Western Pacific, 45, Article ID: 101031. [Google Scholar] [CrossRef] [PubMed]
[26] Li, J., Cui, T., Huang, Z., Mu, Y., Yao, Y., Xu, W., et al. (2023) Analysis of Risk Factors for Lymph Node Metastasis and Prognosis Study in Patients with Early Gastric Cancer: A SEER Data-Based Study. Frontiers in Oncology, 13, Article ID: 1062142. [Google Scholar] [CrossRef] [PubMed]
[27] Huang, S., Chen, T., Hsu, J., Tsai, C., Liu, K., Yeh, C., et al. (2022) Lymph Node Micrometastasis of Poorly Differentiated Node-Negative Gastric Cancer Risks a Worse-than-Expected Survival Outcome under Standard Management Algorithm. European Journal of Surgical Oncology, 48, 783-788. [Google Scholar] [CrossRef] [PubMed]
[28] Yamashita, H., Deng, J., Liang, H. and Seto, Y. (2017) Re-Evaluating the Prognostic Validity of the Negative to Positive Lymph Node Ratio in Node-Positive Gastric Cancer Patients. Surgery, 161, 1588-1596. [Google Scholar] [CrossRef] [PubMed]
[29] Deng, J., Yamashita, H., Seto, Y. and Liang, H. (2016) Increasing the Number of Examined Lymph Nodes Is a Prerequisite for Improvement in the Accurate Evaluation of Overall Survival of Node-Negative Gastric Cancer Patients. Annals of Surgical Oncology, 24, 745-753. [Google Scholar] [CrossRef] [PubMed]
[30] Lv, L., Liang, X., Wu, D., Wang, F., Zhang, Y., Cang, H., et al. (2021) Is Cardia Cancer a Special Type of Gastric Cancer? A Differential Analysis of Early Cardia Cancer and Non-Cardia Cancer. Journal of Cancer, 12, 2385-2394. [Google Scholar] [CrossRef] [PubMed]
[31] Wang, Z., Wang, Q., Chen, C., Zhao, X., Wang, H., Xu, L., et al. (2023) NNMT Enriches for AQP5+ Cancer Stem Cells to Drive Malignant Progression in Early Gastric Cardia Adenocarcinoma. Gut, 73, 63-77. [Google Scholar] [CrossRef] [PubMed]

为你推荐